Atossa Therapeutics (NASDAQ:ATOS) Given New $7.00 Price Target at Ascendiant Capital Markets

Atossa Therapeutics (NASDAQ:ATOS) had its price target upped by Ascendiant Capital Markets from $6.50 to $7.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price indicates a potential upside of 455.56% from the stock’s previous close.

A number of other research analysts have also commented on the company. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. HC Wainwright upped their target price on Atossa Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, November 13th.

Atossa Therapeutics Trading Up 0.8 %

ATOS stock opened at $1.26 on Monday. The stock has a market capitalization of $158.51 million, a price-to-earnings ratio of -5.73 and a beta of 1.22. The firm’s 50-day moving average price is $1.37 and its two-hundred day moving average price is $1.33. Atossa Therapeutics has a 12-month low of $0.70 and a 12-month high of $2.31.

Hedge Funds Weigh In On Atossa Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in shares of Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares during the period. Cetera Advisors LLC purchased a new stake in Atossa Therapeutics in the first quarter worth $72,000. Rhumbline Advisers purchased a new stake in Atossa Therapeutics in the second quarter worth $161,000. Vanguard Group Inc. raised its holdings in Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after purchasing an additional 78,269 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Atossa Therapeutics during the second quarter valued at $29,000. 12.74% of the stock is owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.